Parallax Volatility Advisers
ADMA icon

Parallax Volatility Advisers’s ADMA Biologics ADMA Stock Holding History

Parallax Volatility Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-54,000
Closed -$129K – 2220
2020
Q3 		$129K Buy
+54,000
New +$148K ﹤0.01% 2662

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Parallax Volatility Advisers's ADMA Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of ADMA Biologics (ADMA) in Q4 2020, closing a stake of 52,613 shares — an estimated $126K sold.

Parallax Volatility Advisers first reported a position in ADMA in Q3 2020 and held it in 1 quarter. The position peaked at $126K in Q3 2020. 94 funds tracked by Wall St. Rank hold ADMA as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining ADMA Biologics position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 52,613 ADMA Biologics shares in Q4 2020, an estimated $126K.
  • Parallax Volatility Advisers first reported a position in ADMA Biologics in Q3 2020 and held it in 1 quarter.
  • Parallax Volatility Advisers's ADMA Biologics position peaked at $126K in Q3 2020.
  • 94 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.